ArticleBMJ neurology open2024

Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study.

Trung Dang Quoc Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.